Investing6d
AbbVie and Xilio partner for tumor-activated therapies
The U.S. Food and Drug Administration (FDA) approved AbbVie's novel antibiotic EMBLAVEO for the treatment of adults with complicated intra-abdominal infections. The drug is a significant ...
MM&M4d
AbbVie names CEO Robert Michael as board chair, Richard Gonzalez departs
AbbVie made a change atop its board of directors, naming CEO Robert Michael as chairman on Friday morning. The pharma giant announced that Michael will succeed Richard A. Gonzalez, the former CEO of ...
pharmaphorum1d
FDA clears new antibiotic for superbug infections
AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...
Investing6d
AbbVie and Xilio partner for tumor-activated therapies
The U.S. Food and Drug Administration (FDA) approved AbbVie's novel antibiotic EMBLAVEO for the treatment of adults with complicated intra-abdominal infections. The drug is a significant advancement ...
Daily4d
FDA approves drug combination for complicated intra-abdominal infections
AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...